Our Team

Flavia’s expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics has culminated in the creation of InfectID, a diagnostic test that identifies bacterial, fungal and viral pathogens.

Colin’s recent experience includes the Interim CEO role at MindBio Therapeutics, where he was responsible for building the business to enable sustainable growth post-listing on the Canadian Stock Exchange. This included creating a strategy to facilitate revenue generation and growth capability in the short and medium term; diversifying revenue generation capability and ‘de-risking’ the investment strategy.

Before joining Microbio, Lutz served as Senior Vice President and General Manager, Commercial Operations Europe at CSL Behring, where he spent two decades shaping commercial strategy for rare disease therapies, plasma derived medicines, and emerging modalities including gene therapy and advanced therapy medicinal products. His blend of commercial leadership, scientific depth, and patient-focused perspective positions him to guide Microbio’s next phase of global commercial growth.

 Lutz holds a degree in pharmacy and a PhD in Microbiology from the Max Planck Institute for Terrestrial Microbiology and Philipps University Marburg.

Having held operational positions, CEO roles, and board positions across a diverse range of industries including agriculture and health related assets, James will focus on Microbio’s strategic direction, business processes, and governance structures to drive sustainable company growth.